Is Sheep Ghee Cardioprotective?
Effect of Sheep Ghee on Lipid Profile and High-sensitivity C-reactive Protein: A Randomized Clinical Trial
1 other identifier
interventional
50
1 country
1
Brief Summary
Normal volunteers were randomly received Sheep ghee or sunflower oil, and before and after the study lipid profile and HS-CRP were measured.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Feb 2020
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2022
CompletedFirst Submitted
Initial submission to the registry
August 5, 2022
CompletedFirst Posted
Study publicly available on registry
August 8, 2022
CompletedAugust 8, 2022
August 1, 2022
2.3 years
August 5, 2022
August 5, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
LDL cholesterol
serum LDL level in mg/dl
2 months
total cholesterol
serum total cholesterol in mg/dl
2 months
HDL cholesterol
Serum HDL in mg/dl
2 months
HS-CRP
HS-CRP level in picogram/dl
2 months
Secondary Outcomes (1)
adverse effect
2 months
Study Arms (2)
intervention
EXPERIMENTAL10 gr Sheep ghee
control group
ACTIVE COMPARATOR10 gr sunflower oil
Interventions
natural sheep ghee, given to patient in a commercial box and intervention group 10 gr per day from sheep ghee
natural sunflower oil, given to patients in a commercial box and patient use 10 gr of it
Eligibility Criteria
You may qualify if:
- healthy adults, seeking outpatient visit at professor kojuri cardiology clinic
You may not qualify if:
- any history of ischemic heart disease (IHD),
- coronary artery bypass grafting (CABG)
- percutaneous intervention (PCI)
- stroke
- peripheral vascular diseases
- use of anti-hyperlipidemic agents
- unwillingness to participate.
- Need of tight hyperlipidemia control.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Javad Kojuri
Shiraz, Fars, 7134814336, Iran
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Masking Details
- random allocation, open label
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- professor
Study Record Dates
First Submitted
August 5, 2022
First Posted
August 8, 2022
Study Start
February 1, 2020
Primary Completion
June 1, 2022
Study Completion
July 1, 2022
Last Updated
August 8, 2022
Record last verified: 2022-08